Your browser doesn't support javascript.
loading
Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review.
Currie, Gillian R; Gerber, Brittany; Lorenzetti, Diane; MacDonald, Karen; Benseler, Susanne M; Bernier, Francois P; Boycott, Kym M; Carias, K Vanessa; Hamelin, Bettina; Hayeems, Robin Z; LeBlanc, Claire; Twilt, Marinka; van Rooijen, Gijs; Wong-Rieger, Durhane; Yeung, Rae S M; Marshall, Deborah A.
Afiliación
  • Currie GR; Department of Pediatrics, Health Research Innovation Centre, University of Calgary, Room 3C56, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. currie@ucalgary.ca.
  • Gerber B; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada. currie@ucalgary.ca.
  • Lorenzetti D; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. currie@ucalgary.ca.
  • MacDonald K; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Benseler SM; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Bernier FP; Health Sciences Library, University of Calgary, Calgary, AB, Canada.
  • Boycott KM; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Carias KV; Department of Pediatrics, Health Research Innovation Centre, University of Calgary, Room 3C56, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
  • Hamelin B; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
  • Hayeems RZ; Alberta Health Services, Calgary, AB, Canada.
  • LeBlanc C; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
  • Twilt M; Department of Medical Genetics, Alberta Children's Hospital, Calgary, AB, Canada.
  • van Rooijen G; Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
  • Wong-Rieger D; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.
  • Yeung RSM; Genome Alberta, Calgary, AB, Canada.
  • Marshall DA; Ontario Genomics Institute, Toronto, ON, Canada.
Pharmacoeconomics ; 41(7): 803-818, 2023 07.
Article en En | MEDLINE | ID: mdl-37029233
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Rare diseases place a significant burden on patients, families, the healthcare system, and society. Evidence on the socioeconomic burden of rare disease is limited and mostly reflects diseases where treatments are available. We developed a framework encompassing recommended cost elements for studies of the socioeconomic burden of rare diseases.

METHODS:

A scoping review, conducted in five databases (Cochrane Library, EconLit, Embase, MEDLINE, and APA PsycINFO), identified English language publications from 2000 to 2021 presenting frameworks developed for determining, measuring or valuing costs for rare or chronic diseases. Cost elements were extracted and used to develop a literature-informed framework. Structured feedback was gathered from experts in rare diseases, health economics/health services, and policy research to revise the framework.

RESULTS:

Of 2990 records identified, eight papers were included and informed our preliminary framework; three focused on rare disease and five on chronic disease. Following expert input, we developed a framework consisting of nine cost categories (inpatient, outpatient, community, healthcare products/goods, productivity/education, travel/accommodation, government benefits, family impacts, and other), with several cost elements within each category. Our framework includes unique costs, added from the expert feedback, including genetic testing to inform treatment, use of private laboratories or out-of-country testing, family involvement in foundations and organizations, and advocacy costs for special access programs.

CONCLUSIONS:

Our work is the first to identify a comprehensive list of cost elements for rare disease for use by researchers and policy makers to fully capture socioeconomic burden. Use of the framework will increase the quality and comparability of future studies. Future work should focus on measuring and valuing these costs through onset, diagnosis, and post-diagnosis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atención a la Salud / Enfermedades Raras Tipo de estudio: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Aspecto: Determinantes_sociais_saude Límite: Humans Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Atención a la Salud / Enfermedades Raras Tipo de estudio: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Aspecto: Determinantes_sociais_saude Límite: Humans Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Canadá